Dance Biopharm has announced the appointment of Phillips-Medisize President and CEO Matt Jennings to its board of directors. Phillips-Medisize is developing a connected version of Dance’s insulin soft mist inhaler device. Jennings joined Phillips-Medisize as Chairman, CEO and President in 2011; his prior experience includes 5 years as President of Teleflex and 2 … [Read more...] about Phillips-Medisize CEO Matt Jennings appointed to Dance Biopharm board of directors
News
Milestone Pharmaceuticals raises $80 million for Phase 3 development of intranasal etripamil
Milestone Pharmaceuticals said that it has completed an $80 million financing round led by RTW Investments, a new investor. Proceeds will be used for Phase 3 development of its intranasal etripamil for the treatment of paroxysmal supraventricular tachycardia (PSVT), which recently got underway, for certain commercial activities prior to an anticipated launch of the … [Read more...] about Milestone Pharmaceuticals raises $80 million for Phase 3 development of intranasal etripamil
Acerus Pharmaceuticals initiates Phase 1 study of intranasal cannabis oil
Acerus Pharmaceuticals has announced the initiation of a Phase 1 clinical trial of an intranasal formulation of cannabis oil, which the company said is "a preliminary step in a broader strategy focused on identifying additional applications for Acerus’ proprietary nasal delivery technology, including for prescription medical marijuana." The company has developed … [Read more...] about Acerus Pharmaceuticals initiates Phase 1 study of intranasal cannabis oil
Positive Phase 2b results for both Oyster Point nasal sprays for dry eye disease
Oyster Point Pharma has announced that separate Phase 2b studies of its OC-01 and OC-02 nicotine acetylcholine receptor (nAChR) agonist nasal sprays for the treatment of dry eye disease both showed improvement in dry eye symptoms for patients using the nasal sprays. Positive results for a previous Phase 2b trial of OC-2 were announced in July 2018. Oyster Point … [Read more...] about Positive Phase 2b results for both Oyster Point nasal sprays for dry eye disease
Biohaven Pharmaceutical initiates Phase 1 study of intranasal migraine candidate
Biohaven Pharmaceutical said that it has initiated a Phase 1 trial of its BHV-3500, an intranasal calcitonin gene-related peptide (CGRP) receptor antagonist delivered via the Aptar Pharma Unit Dose System after the FDA approved its IND. The trial will evaluate various doses of BHV-3500, which the company is developing for the treatment of migraine.The company … [Read more...] about Biohaven Pharmaceutical initiates Phase 1 study of intranasal migraine candidate
FSD Pharma to acquire Therapix Biosciences
Canadian cannabis grower FSD Pharma has signed a letter of intent to acquire Therapix Biosciences for $48 million, the company said. Therapix has licensed intranasal cannabinoid delivery technology from Yissum Research Development Company, which is the technology transfer company for Hebrew University, and cannabinoid researcher Raphael Mechoulam of Hebrew University … [Read more...] about FSD Pharma to acquire Therapix Biosciences
Lindal launches Cyrano nasal actuator
Lindal Group has launched a new nasal actuator called Cyrano, which has a rounded asymmetric pyramidal shape. According to the company, the actuator shape preventing insertion of the device too far into the nose, and Cyrano is intended for use across the infant, pediatric, and adult markets. The actuator also is designed to prevent liquid from being retained in the … [Read more...] about Lindal launches Cyrano nasal actuator
New MDI manufacturing facility opened in Morocco
A joint venture of Cipla, Cooper Pharma, and the Pharmaceutical Institute has constructed a new metered dose inhaler manufacturing plant in a suburb of Rabat, Morocco that opened officially as of October 14, 2018. The $6.4 million plant is situated on a 4,000 sq m site and has a capacity of 1.5 million MDIs per year. Eleven of the 15 different SKUs of MDIs … [Read more...] about New MDI manufacturing facility opened in Morocco
Seurat Therapeutics gets $510,000 grant for development of intranasal migraine therapy
Seurat Therapeutics, a start-up biotech based at the University of Chicago, has received a grant of almost $510,000 from the National Institute of Neurological Disorders and Stroke for development of its intranasal IGF-1 for the treatment and prevention of migraines, the company said. In 2016, Seurat, then called Cephalgia, received $250,000 from the University of … [Read more...] about Seurat Therapeutics gets $510,000 grant for development of intranasal migraine therapy
CHMP adopts positive opinion regarding Bevespi Aerosphere MAA
According to AstraZeneca, the EMA's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion regarding the marketing authorization application for the company's Bevespi Aerosphere glycopyrronium/formoterol fumarate MDI for the treatment of COPD. Bevespi Aerosphere was approved by the FDA for marketing in the US in 2016. The MDI is also … [Read more...] about CHMP adopts positive opinion regarding Bevespi Aerosphere MAA